Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.895 -0.085 (-2.14%)

Streaming Delayed Price Updated: 10:01 AM EST, Feb 9, 2026 Add to My Watchlist

Price and Volume

Volume	3,363,534
Open	3.950
Bid (Size)	3.890 (6,300)
Ask (Size)	3.900 (9,700)
Prev. Close	3.980
Today's Range	3.850 - 3.960
52wk Range	3.540 - 12.36
Shares Outstanding	168,425,907
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This $4 Stock Could Be Your Ticket to Millionaire Status ↗

February 07, 2026

It's a potential game-changing technology. The company just needs to prove to the world that it works well enough.

Via The Motley Fool

Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions

February 06, 2026

In a landmark achievement for computational biology, researchers from Harvard Medical School and the Centre for Genomic Regulation (CRG) have unveiled PopEVE, a groundbreaking artificial intelligence...

Via TokenRing AI

Performance

YTD	-7.3%	-7.3%
1 Month	-16.4%	-16.4%
3 Month	-13.6%	-13.6%
6 Month	-26.4%	-26.4%
1 Year	-49.1%	-49.1%

More News

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

Via TokenRing AI

Forget 2025: These 2 Growth Stocks Could Soar in 2026 ↗

January 29, 2026

Via The Motley Fool

Can This Beaten-Down AI Stock Bounce Back in 2026? ↗

January 28, 2026

Via The Motley Fool

2 AI Stocks to Buy in 2026, and 1 to Avoid ↗

January 16, 2026

Via The Motley Fool

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

January 12, 2026

Via TokenRing AI

From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance

January 12, 2026

Via MarketMinute

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

Via TokenRing AI

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

January 01, 2026

Via TokenRing AI

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗

January 01, 2026

Via The Motley Fool

Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026

December 25, 2025

Via MarketMinute

Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…

December 17, 2025

Via AB Newswire

Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗

December 17, 2025

Via The Motley Fool

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why ↗

December 17, 2025

Via Benzinga

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗

December 17, 2025

Via Stocktwits

Why Recursion Pharamaceuticals Topped the Market Today ↗

December 08, 2025

Via The Motley Fool

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

December 08, 2025

From Recursion Pharmaceuticals, Inc.

Via GlobeNewswire

Jim Cramer: This Health Care Stock Has Been 'Horrendous' ↗

December 05, 2025

Via Benzinga

10 AI Stocks Worth Buying Right Now ↗

December 04, 2025

Via The Motley Fool

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

Via MarketMinute

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Via TokenRing AI

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

December 01, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery

November 25, 2025

Via TokenRing AI

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?

Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.

What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?

Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market

What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 3.895

When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?

The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 02/09/26 10:01 AM ET

What is the market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock?

The market capitalization of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 656.02M

How many shares of Recursion Pharmaceuticals, Inc. - Class A Common Stock are outstanding?

Recursion Pharmaceuticals, Inc. - Class A Common Stock has 656M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.